Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Viking Thera (NQ: VKTX )

67.10 +0.37 (+0.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,941,301
Open 66.21
Bid (Size) 67.08 (1)
Ask (Size) 67.30 (10)
Prev. Close 66.73
Today's Range 64.54 - 68.83
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Terns Pharmaceuticals just proved that it's competitive in the weight loss field. 
Via The Motley Fool
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
The major indexes reclaimed key levels and many leaders flashed buy signals. 
Via Investor's Business Daily

Performance

YTD
+267.07%
+267.07%
1 Month
+0.71%
+0.71%
3 Month
+28.99%
+28.99%
6 Month
+5.92%
+5.92%
1 Year
+385.70%
+385.70%

More News

Read More
These 2 Biotech Stocks Are Set to Soar
Via The Motley Fool
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Via The Motley Fool
Why Investors Plowed Into Viking Therapeutics Stock Today
Via The Motley Fool
Viking Therapeutics Unusual Options Activity For September 11
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $7,500 Today
Via Benzinga
(VKTX) - Analyzing Viking Therapeutics's Short Interest
Via Benzinga
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
Via The Motley Fool
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
Via Benzinga
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
Via Investor's Business Daily
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Viking Therapeutics
Via Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Prediction: This Biotech Stock Will Outperform Nvidia in the Second Half of the Year
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Via Benzinga
Why Viking Therapeutics Stock Got Thrashed on Tuesday
Via The Motley Fool
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Via Investor's Business Daily
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
Via The Motley Fool
Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping?
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.